Cargando…

Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease

Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Mi Jin, Choe, Yon Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760698/
https://www.ncbi.nlm.nih.gov/pubmed/24010109
http://dx.doi.org/10.5223/pghn.2013.16.2.65
_version_ 1782282785426243584
author Kim, Mi Jin
Choe, Yon Ho
author_facet Kim, Mi Jin
Choe, Yon Ho
author_sort Kim, Mi Jin
collection PubMed
description Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine. The dose of azathioprine has to be reduced or the therapy has to be discontinued frequently because of drug-induced toxicity. In this review, we discuss monitoring of thiopurines, adverse events, malignant complications and how to use azathioprine safely and usefully.
format Online
Article
Text
id pubmed-3760698
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition
record_format MEDLINE/PubMed
spelling pubmed-37606982013-09-05 Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease Kim, Mi Jin Choe, Yon Ho Pediatr Gastroenterol Hepatol Nutr Invited Review Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine. The dose of azathioprine has to be reduced or the therapy has to be discontinued frequently because of drug-induced toxicity. In this review, we discuss monitoring of thiopurines, adverse events, malignant complications and how to use azathioprine safely and usefully. The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2013-06 2013-06-30 /pmc/articles/PMC3760698/ /pubmed/24010109 http://dx.doi.org/10.5223/pghn.2013.16.2.65 Text en Copyright © 2013 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Invited Review
Kim, Mi Jin
Choe, Yon Ho
Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease
title Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease
title_full Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease
title_fullStr Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease
title_full_unstemmed Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease
title_short Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease
title_sort monitoring and safety of azathioprine therapy in inflammatory bowel disease
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760698/
https://www.ncbi.nlm.nih.gov/pubmed/24010109
http://dx.doi.org/10.5223/pghn.2013.16.2.65
work_keys_str_mv AT kimmijin monitoringandsafetyofazathioprinetherapyininflammatoryboweldisease
AT choeyonho monitoringandsafetyofazathioprinetherapyininflammatoryboweldisease